Breccia et al. performed a study of 7 diabetic subjects with CML treated with imatinib, 6 showed improvements in fasting glucose concentrations, allowing a dose decrease of oral hypoglycemic agents and insulin. The gene discussed is INS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.